Voting Open for the 2015 Election for BAP Council Members

The following vacancies will arise on Council in July:

**Two Elected Council Member posts**

**(Post 5)** This post has been vacant since 2014 following Dr Elizabeth Tunbridge's election to the post of Honorary Treasurer

**(Post 6)** Dr Mitul Mehta will retire

Council Post 9 was created in 2011 following an election tie and will cease to exist on 28 July 2015.

**All Full, Honorary and Retired Full Members are eligible to vote.**

Voting will be online via the website only from Wednesday 20 May and will close on Monday 6 July.

[www.bap.org.uk/vote](http://www.bap.org.uk/vote)

The BAP aims to represent the interests of all psychopharmacologists (pre-clinical, clinical and industrial) regardless of gender or ethnic origins. To achieve this it is essential that Council represents all constituents of the BAP. Council asks Members to bear this in mind when casting their votes in the election, to ensure a balance of expertise.

continued on page 3
School of Chemistry, University of Bristol, UK
Sunday 26th to Wednesday 29th July 2015

Highlights

**2015 Guest Lecture** to be presented by Elizabeth Binder from Emory University – Genetically determined differences in the immediate transcriptome response to stress predict risk-related brain function and psychiatric disorders

**Clinical Masterclass** led by Stephen Stahl

**Pre-Clinical Workshop** – A new 3Rs challenge for animal research in psychiatry: reproducibility, relevance, reverse translatability

**Post-Doc Symposium** – Neurobiological Mechanisms of Treatment and Response to Treatment

**Short Orals** – Mood and Reward | Schizophrenia: From PCP to Practice | Early Life Stress and Depression

9 invited symposia covering cutting-edge clinical and non-clinical psychopharmacology:

**Monday 27th July** – Use and abuse of novel psychoactive substances | Bipolar disorder: looking to the future | Of models and men: translational imaging studies in advancing mechanistic understanding of neuropsychiatric diseases

**Tuesday 28th July** – Where now for glutamatergic strategies for schizophrenia? | Sleep and drugs in the 21st century | The Electronic cigarette: from basic pharmacology to smoking harm reduction and cessation

**Wednesday 29th July** – Advances in compulsivity: a trans-diagnostic perspective | The role of synaptic proteins in schizophrenia and related neurodevelopmental disorders | Non-invasive neurostimulation

**Welcome Drinks Reception** at the Royal West of England Academy of Art

**Conference Dinner** at Bristol Grammar School including presentation of the 2015 Prizes and Awards

**EARLY BIRD REGISTRATIONENDS 8 JUNE 2015**

For full details of the meeting go to [www.bap.org.uk/summermeeting2015](http://www.bap.org.uk/summermeeting2015)
Current Officers and Council

**ELECTED OFFICERS**

- Professor Paul Harrison  
  President
- Professor Jo Neill  
  President-Elect
- Professor Barbara Sahakian  
  Past-President
- Dr Elizabeth Tunbridge  
  Honorary Treasurer
- Professor Marcus Munafo  
  Meetings Secretary
- Dr Maxine Patel  
  Honorary General Secretary
- Dr Oliver Howes  
  Secretary for Clinical External Affairs
- Dr Paula Moran  
  Secretary for Non-Clinical External Affairs

**ELECTED COUNCIL MEMBERS**

- Dr Sarah Bailey (Post 1)
- Dr James Stone (Post 2)
- Dr Carmine Pariante (Post 3)
- Professor Ed Bullmore (Post 4)
- Vacant (Post 5)
- Dr Mitul Mehta (Post 6)
- Professor Peter Jones (Post 7)
- Dr Ciara McCabe (Post 8 – filling a casual vacancy until July 2016)
- Dr Hugh Marston (Post 9)

Candidates’ Biographies and Statements

**Michael Browning**  
*Department of Psychiatry, Oxford*

**Proposer:** Professor Guy Goodwin  
**Seconder:** Professor Marcus Munafo

The BAP fulfils a unique role in the UK. Its annual conference is the key national forum in which new treatment and aetiological based biological research is presented, meaning that it is the best place to present your own work and to find out what others in your area are doing. Its educational program, which includes clinical masterclasses and the preclinical psychopharmacology course, provides robust evidence based information for both clinicians and preclinical scientists. Lastly, the BAP’s public engagement activities help to promote a balanced understanding of the role of psychopharmacology. As a result, the BAP has become an essential component in supporting and encouraging the development of young researchers and in representing psychopharmacology at the national level.
Over the many years I have been a member of the BAP it has supported me financially to attend oversees conferences as well as providing a national platform to present my work. More importantly than this, most of the researchers and research active clinicians I know in the UK I have met at the BAP conference.

I am a clinical researcher with a specific interest in the emotional disorders and the mechanisms by which the treatments of these illnesses exert their effects. I am based in the Department of Psychiatry in Oxford and also work for the contract research organisation P1vital. My current research includes both academic based studies which investigate mechanistic questions and industry sponsored studies which apply similar techniques in the assessment of novel treatments.

In my opinion the two key priorities for the BAP should be 1) to continue to develop the support provided for early career researchers and 2) to develop the liaison between the BAP and industry with the goal of promoting the translation of recent research advances into tangible gains for patients. I suspect it is also pretty important to make sure there is always some form of disco at the conference.

Ciara McCabe
University of Reading

Proposer: Professor David Nutt
Seconder: Professor Catherine Harmer

Ciara McCabe is Associate Professor of Neuroscience at the University of Reading (Head: Neuroimaging of Reward Group: NRG) www.ciaramccabe.co.uk/nrg.html where she collaborates with preclinical (Prof Claire Williams and Prof Ben Whalley: psychopharmacology), clinical (NHS Charlie Waller Institute and Berkshire Health Foundation Trust) and industry scientists (GWPharma Ltd and Forest Laboratories, INC, USA) to examine human reward dysfunction in depression and the effects of antidepressant treatments on the neural response to reward.

Ciara completed a degree in Psychology from Queens University, Belfast in 1998. In 2003 she obtained a PhD from the University of Ulster on preclinical models of anxiety involving frustrative non-reward and anxiolytic treatment effects (Merck, Sharpe and Dohme funding). In 2003 she joined Prof Mike Nader’s lab at Wake Forest University, NC, USA, where she investigated non-human primate self-administration models of cocaine addiction. She moved in 2005 to Prof Rolls lab in Experimental Psychology, Oxford University where she developed a human neuroimaging model using chocolate to examine reward. In 2007 she moved to the Psychiatry Dept, Oxford University and combined her interests with that of Prof Phil Cowen and Prof Catherine Harmer in human psychopharmacology with neuroimaging studies in those “at risk” of psychiatric disorders and the effects of antidepressant treatments on the neural response to reward and aversion.

Ciara has attended every summer BAP meeting since 2008. In 2008 she was awarded a British Association of Psychopharmacology (BAP) Lilly Fellowship and in 2010 she was awarded a European College of Neuropsychopharmacology (ECNP) Fellowship Award to attend the annual meeting in Amsterdam. In 2012 she was awarded The International College of Neuropsychopharmacology (CINP) Rafaelsen Young Investigator’s Award, as part of the biannual meeting in Stockholm. In 2014 she received a University of Reading Celebrating Success Award.

Ciara is active in public engagement and has appeared on prime time TV; e.g. Channel 4 Dispatches and BBC 1 programmes. She has also spoken many times on Radio about her work in depression and has also appeared in print e.g. The Guardian. She also spoke at the Cheltenham Science Festival and the Institute of Physics Public Lecture series in 2014 and will talk at SciBar in Oxford, Reading’s Cafe Sci and the University of Reading Public Lecture series in 2015 about her work on the neurobiology of depression and anti-depressant treatment.

Ciara is also director of Outreach for the Psychology Department and sits on the Athena Swan Committee and the Executive Committee of the Centre for Neuroimaging and Neurodynamics (CINN) at the University of Reading. Ciara has also recently been elected to the Board of Trustees for the UK charity Immigrant Counselling and Psychotherapy (ICAP)
Valeria Mondelli  
*King's College London*  
**Proposer:** Dr Mitul Mehta  
**Seconder:** Dr Hamish McAllister-Williams  
I am a Senior Clinical Lecturer at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London. I have been interested in research in psychopharmacology since 1999 when I was still a medical student in Italy. During my rotation in General Adult Psychiatry (2000-2004) and whilst still in Italy, I started to conduct various research projects in psychopharmacology and psychoneuroendocrinology of eating disorders. Because of my interest in psychiatric research and my commitment to an academic career, I relocated to UK in 2005 to work at the IoPPN, where I completed my PhD in 2009.

Since the first year I arrived in London, I started attending regularly the BAP summer meetings which I have always considered integral part of my academic and clinical development. I have been honoured to receive the junior clinical BAP Psychopharmacology award in 2010 and the BAP/Cambridge Cognition Award in 2012 for some of my work on the role of hypothalamic-pituitary-adrenal (HPA) at the onset of psychosis and on the association between neurotrophic factors, inflammation and brain structure in patients with first episode psychosis. I have always particularly valued the educational activities offered by the BAP as well as the consistently exciting programmes of the summer meetings. The BAP summer meetings have also opened my way to a fantastic network of scientists which have fostered over the years not only important scientific collaborations, but also precious friendships.

Since 2013 I have been appointed as deputy lead for the NIHR Biomedical Research Centre Experimental Medicine and Clinical Trials cluster at IoPPN; in 2014 I have been promoted to my current position of Senior Clinical Lecturer. My current research focuses on the role of stress and of biological systems involved in the stress response in the pathogenesis of psychiatric disorders and in the interplay between physical and mental health.

I would extremely value the opportunity of becoming a BAP council member and of contributing to the continued successful activity of the BAP both for the current members and for those to come. I am particularly interested in enhancing the role of women in academia and I think the BAP could play a pivotal role in this area by organizing specific educational events and by increasing visibility and networking for junior academic women. I would also like to further develop the BAP focus on the interplay between physical and mental health which has also recently contributed to a renewed interest of pharmaceutical industry in mental health.

Angela Roberts  
*University of Cambridge*  
**Proposer:** Professor Barbara Sahakian  
**Seconder:** Professor Trevor Robbins  
Angela Roberts graduated from the University of Sussex (1981) with a degree in Neurobiology. She obtained her PhD in neuroendocrinology (1985) from the laboratory of Professor Joe Herbert, Department of Anatomy, University of Cambridge. She had by then developed a strong interest in behavioural and cognitive neuroscience and so joined the Department of Experimental Psychology at Cambridge, first as a Wellcome Trust Postdoctoral Associate with Professor Trevor Robbins and then as a Royal Society University Research Fellow studying the neural and neurochemical basis of cognitive flex-

May 2015. Ciara has also recently become an Associate Fellow of the Higher Education Authority, 2015.  
Ciara holds the BAP in high regard and believes the association’s strengths lie in its ability to attract both preclinical and clinical scientists to forge strong collaborative translational work.
Mental health research faces an increasingly challenging environment through the withdrawal of “big pharma” from psychiatry, reductions in mental healthcare provision and ever more competitive research grant funding. Against this background, the BAP provides a vitally important role in supporting research, providing education and outreach, and inspiring future leaders in psychopharmacology. If elected to council, I will do my utmost to advance the goals and development of the BAP. I’m particularly keen to support the BAP’s work in engaging with the public and the government about the importance of mental health research. I’ve also learnt a lot from working with organisations such as Bipolar UK and I think it would be fantastic if we could incorporate expertise from patients and other mental health charities into the work of the association. Finally, the BAP’s work in developing collaborative research networks is hugely important for psychopharmacology research in the UK and I hope I can contribute to this through my experience in setting up and chairing the CRN Mental Health Bipolar Disorder clinical trials research network.

My interest in the brain and psychopharmacology started at medical school in Birmingham whilst studying for an intercalated BSc in pharmacology. This inspired me to train in psychiatry at the Maudsley Hospital and I was very fortunate to then work with Paul Grasby at the MRC Cyclotron Unit where I investigated the effect of risk factors for psychosis on human dopamine function. I have fond memories of giving my first (rather nervous) scientific presentation.
presentation at the BAP conference in 2005 and will always be grateful to the BAP for this opportunity. I returned to the Maudsley to complete specialist training in psychiatry and then worked with Anne Lingford-Hughes and David Nutt at Imperial College London to investigate the human GABA system and the role of dopamine in addictions. I developed an interest in bipolar disorder working with Allan Young and in 2013 I joined the Centre for Affective Disorders at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London. In my clinical work there, I provide specialist assessments and treatment plans for people with treatment resistant depression and bipolar disorder. My research is focused on improving the mental health of people with mood disorders by using neuroimaging to better understand disease mechanisms and using clinical trials to evaluate new treatments.

Peter Talbot
University of Manchester

Proposer: Professor Thomas Barnes
Seconer: Professor Jo Neill

I qualified in Medicine from the University of Bristol, and completed my specialist clinical training and MD in Psychiatry in Northern Ireland, the country of my birth. My postdoctoral research training was in Positron Emission Tomography (PET) neuroimaging under the supervision of Marc Laruelle at Columbia University in New York, followed by appointment as Assistant Professor in Psychiatry there in 2004. I joined the University of Manchester in 2005 and am currently Senior Lecturer in Molecular Neuroimaging and Associate Director of the Wolfson Molecular Imaging Centre. My primary research interest is the use of PET to investigate abnormal brain mechanisms in severe mental illness, particularly psychosis, affective disorders and impulsivity. I am active in neuroscience and psychopharmacology teaching both locally (Lead for undergraduate and postgraduate modules; Chair of the Affective Disorders Group North West) and nationally for the BAP (Course Organiser for the Schizophrenia Module; lecturer on the Affective Disorders Module and Depression Masterclass). I am an Honorary Consultant Psychiatrist with Manchester Mental Health and Social Care Trust and Director of the Specialist Service for Affective Disorders, a regional tertiary-level NHS clinic.

I have been an active member of BAP for over 15 years (BAP Certificate in Psychopharmacology, 2001). Throughout my training I found the BAP’s Education & Training programmes invaluable and as a researcher I greatly value the Summer Meeting as an opportunity to share cutting edge research with clinical and preclinical colleagues. I am well aware of the importance of BAP in providing informal support and mentorship especially to younger members starting out in their careers. For the last 8 years I have been actively involved in a wide range of BAP teaching programmes - I taught on the Masterclass in Schizophrenia 2007-2012, was Scientific Editor for its on-line CPD module until 2012, have been Course Organiser and lecturer on the Schizophrenia Module of the Clinical Certificate since 2012, and for the last 2 years I have also taught on the Affective Disorders Certificate Module and Depression Masterclass. I am now at a stage where I wish to take a more active role in BAP by serving on Council.

My work as an academic involved in clinical and basic science research, plus my clinical work as an Honorary NHS Consultant, means I am well placed to represent the full BAP membership on Council. Pressures on undergraduate and postgraduate curricula, rapidly changing clinical guidelines, information overload, and the anti-medication scepticism of a vocal section of mental health professionals and the public ensure that the need for accurate, balanced, independent, evidence-based information on medications for mental disorders has never been greater. If elected to Council, I will work to promote and maintain the role of the BAP as provider of choice for high-quality information, education and training for clinicians at all levels – as well as to patients, carers and the public. One of the BAP’s very great strengths is its multidisciplinary nature – Clinical Psychiatry, Pharmacy, Preclinical and Industry. I believe that good medicine needs strong collaboration between these disciplines of the highest scientific and ethical standards, and I will be active in seeking to maintain and promote this cross-disciplinary interaction.
Anthony Vernon  
_institute of Psychiatry, King's College London_

**Proposer:** Professor Shitij Kapur

**Seconder:** Professor Judy Pratt

I trained in Biochemistry (B.Sc.) and Neuropharmacology (Ph.D.) at Imperial College London. I then moved to the Institute of Psychiatry, Psychology and Neuroscience at King’s College London where I was an Edmond J Safra Research Fellow and an MRC postdoctoral fellow, before being appointed to my present post of Lecturer in the Department of Basic and Clinical Neuroscience. I am also a member of the Psychosis Clinical Academic Group.

I lead a research group focused on translational neuropsychopharmacology. We have pioneered an integrated biomedical imaging approach comprising in vivo Magnetic Resonance Imaging (MRI) and ex vivo optical imaging (CLARITY) that facilitates parallel studies in humans and rodent models. Specifically, we are interested in the effects of both therapeutic (antipsychotics, levodopa) and drugs of abuse (ketamine, cannabinoids) on brain structure and function, particularly when administered during vulnerable windows of brain development such as in utero or during adolescence. The goal of this work is to increase our understanding of both the therapeutic and adverse effects of these compounds and provide mechanistic explanations for the links between drug abuse in adolescence and increased risk for psychiatric disorders in adulthood. Importantly, by running parallel studies in humans and animals using clinically comparable technology (MRI) we seek to bridge scales and link macroscale neuroimaging signal changes to their microscale cellular correlates.

I collaborate with a number of colleagues at King’s, as well as elsewhere in the UK and abroad including the Centre for Addiction and Mental Health in Toronto. I have received funding support from the Medical Research Council, Wellcome Trust, The Royal Society, Guy’s and St. Thomas’ Charitable Trust and the Psychiatry Research Trust as Principle and co-investigator. My work has led to numerous publications in journals such as Biological Psychiatry and the award of a Translational Research Prize from the CINP (2012) and the ECNP Fellowship award (2011 and 2012).

The BAP is then a vital and unique organisation, a great source of support, education and collaboration and I would welcome this chance to give something back by serving on the BAP council. I was first introduced to the BAP at the Summer Meeting in 2011, where I was impressed immediately by the breadth and depth of the science, the mixture of pre-clinical and clinical research and by the friendly and supportive atmosphere that the society engenders. I gave my first presentation at the following BAP Summer meeting in 2012 as a Young Investigator and have not missed a meeting since. The BAP offers an invaluable platform for pre-clinical and clinical researchers, along with colleagues from the pharmaceutical industry to meet and forge collaborative partnerships. In addition, the commitment the BAP makes to education and training is also hugely important to me, particularly with respect to in vivo research skills.

As a Council Member, I would seek to advance psychopharmacology on all fronts, supporting research, education, and public engagement. I would use this opportunity to ensure the continuation and development of the non-clinical certificate in psychopharmacology and the in vivo training initiative, which I believe are important initiatives to ensuring skills in this area are maintained. I am well placed to do this since I am trained primarily as an animal researcher (15 years experience). I can also contribute to translational research education since my laboratory has pioneered the use of Magnetic Resonance Imaging (MRI; clinically comparable technology) to facilitate translation of our findings to and from human studies and I involved in research projects with parallel clinical and pre-clinical arms, investigating the effects of antipsychotics and other drugs humans and animals. Through this, I hope I will be able to ensure the continuing investment in the next generation of young psychopharmacology researchers.
**Professor Anne Lingford-Hughes receives Academic Women in Psychiatry Award**

The Academic Women in Psychiatry Award is an initiative of the Professors of Psychiatry (PoP) Club, an association that furthers the interaction among academic and consultant psychiatrists through social and educational events. Under the Chairmanship of Professor Carmine M. Pariante, the Executive of the PoP Club had been discussing how to help enhance the careers of academic women in psychiatry, in the spirit of a number of national and international similar initiatives (such as the Athena SWAN Charter).

Following this discussion, in February 2015 the Executive launched an annual Award to recognise a female Professor of Psychiatry. The aim of the Award is to recognise the life-long academic achievements of female Professors of Psychiatry who have both shaped academic psychiatry and inspired subsequent generations. Following its launch, the Award has been very successful: ten senior academics nominated a total of seven outstanding candidates.

The panel was unanimous in its decision to make the 2015 Award to Professor Anne Lingford-Hughes, previous Council member and General Secretary of BAP.

The award was presented to Anne on the occasion of the Hamid Ghodse Lecture on the 20th of April, and was supported in part by Professor Ghodse’s widow, Barbara, to honour Hamid’s legacy as the Chair of the PoP Club until 2012.

The BAP Council extends warm congratulations to Anne on this well-deserved Award.

---

**Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines**

**Abstract**

A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines were then revised after extensive feedback from participants and interested parties. A literature review is provided which identifies the quality of evidence upon which the recommendations are made. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment. Significant changes since the last guidelines were published in 2008 include the availability of new antidepressant treatment options, improved evidence supporting certain augmentation strategies (drug and non-drug), management of potential long-term side effects, updated guidance for prescribing in elderly and adolescent populations and updated guidance for optimal prescribing. Suggestions for future research priorities are also made.

The new guidelines are now on the BAP website: www.bap.org.uk/guidelines.
Trevor Robbins is Professor of Cognitive Neuroscience and Experimental Psychology, and Head of the Department of Psychology, University of Cambridge. Internationally recognised for his outstanding research and original thinking in the areas of cognition and behaviour, his work on the neurobehavioural mechanisms of reward and motivation has proven groundbreaking. Similarly, he has made a highly influential contribution to our understanding of the neurobiology of attention and decision-making. From a technological perspective, his co-invention of CANTAB, a computerised neuropsychological battery, currently used in over 700 institutes and clinical centres worldwide has had a major role in, and impact on, clinical neuroscience research.

Trevor completed a Natural Sciences BA in Psychology, First Class Honours (1971) at Jesus College, University of Cambridge. Continuing at Cambridge, he obtained his PhD in 1975. His thesis ‘An analysis of the behavioural effects of d-amphetamine’ led to numerous high quality publications including one in Nature with Sue Iversen. Following his PhD he transferred to the Faculty staff of the Experimental Psychology Department, initially as a Demonstrator, eventually firmly establishing his base in Cambridge, where he has stayed ever since, apart from three highly productive spells as a visiting researcher at Harvard with Peter Dews, the Salk Research Institute with Floyd Bloom and George Koob and lastly the Institute of Neurology with the late David Marsden and Elizabeth Warrington. In 1997 he was appointed Professor of Cognitive Neuroscience at the University of Cambridge and became Head of the Experimental Psychology Department in 2002 upon his election to the Chair in Experimental Psychology (1931). In 2005 he both became a Fellow of the Royal Society and, with Professor Ed Bullmore, established the MRC-Welcome Trust Behavioural and Clinical Neuroscience Institute. He was made CBE in the New Year’s Honour List in 2012 “for services to medical research”.

He has received many academic awards. In 1982 he received the British Psychological Society’s Spearman Medal for outstanding research and in 1996 the D M Marquis Award for the best paper in Behavioural Neuroscience from the American Psychological Association. In 2001 he received the inaugural Distinguished Achievement Award from the European Behavioural Pharmacology Society and in 2005 he shared the IPSEN Fondation ‘Neuronal Plasticity’ Prize. In 2006 he gave the Fred Kavli Distinguished International Lecture for the Society of Neuroscience. More recently in 2011 the American Psychological Society recognised his Distinguished Scientific Contribution (together with Barry Everitt for their work in collaboration). In 2012 he received the Behavioural Brain Research Award by the European Brain and Behaviour Society and in 2014 he shared the prestigious and valuable ‘Brain Prize’ of the Grete Lundbeck European Brain Research Foundation with S Dehaene and G Rizzolatti for “research on human cognitive disorders”.

Trevor’s research has spanned the whole range of cognitive and behavioural neuroscience and he has done high quality work in neuropsychology.
and psychopharmacology. He has been particularly concerned with the functions of the fronto-striatal-limbic systems in cognitive and executive functions and their modulation by monoaminergic systems. He has conducted his research to test key hypotheses but he has also been interested in how his findings apply to the clinical situation, particularly in relation to addiction and cognitive enhancement. A key theme to all of his work has been the practical and translational application of research findings from rodents to humans and back. This started with the early use of online control of experiments via computing in collaboration with Paul Fray. This, in turn lead to the development of the ‘nine-hole box’ and associated protocols with John Evenden and Mirijana Carli, the primate CANTAB with Angela Roberts and, with Barbara Sahakian and others, human CANTAB, which is now accepted internationally as one of the standard platforms for assessing cognition both in academic and industry settings.

Trevor’s research output has been outstanding, with more than 700 peer reviewed original papers, 70 book chapters or reviews, 70 commentaries and 7 co-edited books. His current H index is an impressive 159 (Web of Science) which puts him in the current top 10 cited neuroscientists worldwide. In addition to his own publications he has guided, as managing editor since 1980, Psychopharmacology, a key journal in the area. A characteristic of his papers is the way they vigorously examine concepts and hypotheses and describe important models to be tested in future research. His more recent papers have similar qualities, but are more translational, involving research on development and in patients with Parkinson’s disease and OCD. Trevor has stimulated and developed major productive collaborations in Cambridge over the years; with Barbara Sahakian (a particularly close collaboration!), Barry Everitt, Angela Roberts, Jeff Dalley and Ed Bullmore, to name but a few.

Trevor has always recognised the importance of developing productive teams of senior and junior researchers and he has been a supervisor and mentor to many successful scientists. He has supervised over 40 successful PhD students of whom about 20 have obtained University Lectureships or higher posts in Research Institutes and industry. He has also supervised about 40 postdoctoral fellows and 8 successful Master’s students.

Over the years Trevor has been in receipt of spectacular grant income which is a testament to his quality. He has received funding particularly from the Wellcome Trust and Medical Research Council, often as long-term programme grants. And he is still going ... he has recently received a Wellcome Trust Senior Investigator Award to investigate fronto-striatal systems and impulsive-compulsive disorders until 2020!

Trevor has made a major contribution to the development of psychopharmacology as a discipline. He was President of the European Behavioural Pharmacology Society from 1992 to 1994, Council Member of the European Neuroscience Association from 1996 to 1999 and President of the British Neuroscience Association from 2009 to 2011. He has made a major contribution to the development of the BAP and its ethos. He was a BAP Council member from 1985 to 1996 and amongst major achievements he was pivotal in putting the administration of the Association on a professional footing. He was President of the BAP from 1996 to 1998 and continues to be a regular attendee at the Summer Meeting, stimulating discussion both at symposia and at poster sessions. He is much in demand as a speaker and as a member of research grant committees, but has always found time for the BAP.

In summary, Trevor has been one of the leading British psychopharmacologists and behavioural scientists of his generation and he is a wonderful example of a researcher who develops and fosters the field. Although he remains as active as ever, his achievements to date mean he is fully deserving of the 2015 BAP Lifetime Achievement Award.

Trevor will receive his Award at the 2015 Summer Meeting Conference Dinner at Bristol Grammar School on Tuesday, 28 July.

Nicol Ferrier
Hugh Marston
Brian Leonard
**Members’ Activities**

*Members’ Activities*

A showcase for the media and public engagement activities of BAP members.

Following are some of the latest members’ activities over the past few months. All members’ activities, with links, can be found at [www.bap.org.uk/members](http://www.bap.org.uk/members)

---

**Ciara McCabe**

**BBC Radio Berkshire**

Ciara talks to Phil Kennedy about her work on reward in relation to depression and anti-depressants 11:40 to 16:56 min.

*13th May 2015*

**Akeem Sule and Becky Inkster (Hip Hop Psych)**

**Kendrick Lamar, street poet of mental health**


*29th April 2015*

**Ciara McCabe**

**The Truth About...Sugar**

Ciara talks to journalist Fiona Phillips about the truth behind the recent headlines on sugar.

*14th April 2015*

**Andrew Mayers**

**Trust Your Instincts**

Andrew talks to Mother and Baby Magazine about new mothers ‘trusting their own instincts’.

*1st February 2015*

---

**Have you recently engaged with the public in science via the media or public events?**

As you may be aware, both the Medical Research Council and the Wellcome Trust advocate engagement with the public regarding scientific and medical research, and BAP is keen for members to engage with the media, so that we can share our important research findings with the public, including enthusiastic students and trainees.

We would like to invite you to share your most recent media activities with us, so that we can disseminate them to the public through our website and social media.

In particular we are looking for media articles, video interviews, podcasts, websites and blogs.

Please send any links or other engagement with the media to Sarah Channing-Wright (sarah@bap.org.uk).
Be part of a respected national academic society that represents UK Neuroscience nationally and internationally

From just £1 per month, take advantage of our many benefits:

- FREE registration for most BNA events, including the stimulating BNA Christmas Symposium in London 🎅
- Reduced registration fees for many other events, including the flagship Festival of Neuroscience
- Reduced registration fees and FENS-sponsored abstract forms for the Society for Neuroscience annual meeting
- Automatic membership of the Federation of European Neuroscience Societies (FENS) and the International Brain Research Organisation (IBRO)
- 50% discount on Society of Biology membership
- 15% off all books from Wisepress, plus journal discounts
- Student prizes and bursaries for BNA and FENS meetings
- Sponsorship of symposia at your University
- BNA Bulletin, the latest neuroscience news, events, studentships and job vacancies
- For more information, visit: www.bna.org.uk, pop us an email or chat to your friendly Local Group Rep!

***Committee positions now available!***

We are now calling for nominations for the following positions: Students & Early Career Representative, Equal Opportunities & Diversity Representative and Membership Secretary. Please visit the BNA website for more details.
April is a lovely month in Venice. The weather is pleasantly warm and the city is not yet overrun with tourists. I was fortunate enough to spend a week there in April 2015 to attend the biannual European College of Neuropsychopharmacology training school on old age neuropsychopharmacology, along with other young psychiatrists from across Europe. ‘Young’ was sensitively defined as under 40 years old, which fits with what I tell my patients – that 80 is the new 60.

The training school took place on the island of San Servolo, about ten minutes by vaporetto from St Mark’s Square. It has an interesting history, having been home to Benedictine monks and nuns for a millennium until the early eighteenth century when the Venetian Republic decided it would be the site of a new military hospital. Its more recent history, appropriately enough for our training school, as a psychiatric hospital will be known to readers of Donna Leon’s novel “Wilful behaviour.” Nowadays, it is a conference venue hosting various academic gatherings throughout the year.

Thus, the fifty or so young psychiatrists and tutors were not the only ones on the island, but I am sure that we were the best taught. Professor Robin Jacoby’s final year organising this school – before handing this task over to Professor Craig Ritchie – was marked by an excellent selection of speakers from across Europe, including Klaus Ebmeier and Rob Howard from the UK, Jose Luis Molinuevo from Spain, and Ingmar Skoog and Margda Waern from Sweden. Each didactic session was paired with case-focused discussion. For example, Professor Waern’s session on suicide in later life was followed by an interactive workshop focused on two or three representative cases she presented.

The beautiful surroundings of the island were most conducive to learning and exchanging ideas. Indeed, one of the highlights for me finding out about how psychiatry is practiced in different countries across Europe. There is much variation in practice and not everywhere has such clear guidance as we do in the UK to guarantee safe practice across the board. Another insight I gained related to external pressures. I learned from a small group of Greek psychiatrists that haloperidol is often the only antipsychotic medication used; due to their country’s dire financial straits, it is the only one they can afford!

Wednesday afternoon was left free to explore Venice and, armed with my second-hand guide book “Venice for pleasure,” I spent an enjoyable time wandering the streets and alleyways and visited the wonderful Peggy Guggenheim collection in her former palazzo on the Grand Canal. This was followed by a long trek getting lost in the back streets of Venice to find a particular restaurant which had taken the fancy of one of the tutors which, once we located it, served the most delicious seafood the lagoon could offer.

I really enjoyed attending this training school and learned a great deal. I think it would be particularly useful to have attended towards the beginning of higher training and will encourage my colleagues to apply for the next old age training school in 2017. I am very grateful to the BAP for nominating me to attend and to the ECNP for covering the costs of the training school and for a partial travel bursary. The ECNP runs numerous training schools and workshops with generous funding available. I would recommend anyone interested to find out more at their website (http://www.ecnp.eu/).
Paper Reviews

There are now 222 published paper reviews on the website. Latest additions include:

- Intravenous ketamine for refractory depression: safety data – 26 March 2015
- Vitamin D and postpartum depression – 25 March 2015
- Factors that increase the placebo response in psychiatry – 14 March 2015
- Age as a predictor of rapid remission with ECT – 05 March 2015
- Nonadherence to psychotropics during pregnancy – 27 February 2015
- Clozapine–related cardiomyopathy – 24 February 2015
- rTMS for Parkinson’s disease: a meta–analysis – 17 February 2015
- ADHD symptoms in adults with epilepsy – 11 February 2015
- Metformin for antipsychotic-related weight gain – 08 February 2015
- Atomoxetine in adult ADHD – integrated analysis of safety and tolerability – 24 January 2015
- Duloxetine vs paroxetine for premature ejaculation – 16 January 2015
- Blonanserin for delirium – 06 January 2015
- A review of ECT in pregnancy – 01 January 2015
- Extended-release memantine – 30 December 2014
- Placebo and the perception of stress as a challenge vs threat – 25 December 2014
- Skin reactions with ziprasidone – 16 December 2014
- Aripiprazole augmentation in depression – 12 December 2014
- Antidepressants and hyponatraemia – 09 December 2014
- Cardiometabolic risks of blonanserin and perospirone – 26 November 2014
- Low dose ondansetron as an augmentation agent in OCD – 24 November 2014
- Drop ‘ins’ in clinical trials – 17 November 2014
- Drop outs in clinical trials – 15 November 2014
- Effect of R-citalopram on serotonergic effects of escitalopram – 09 November 2014
- Smoking cessation treatments and suicide risk – 27 October 2014
- Duloxetine: safety during pregnancy and lactation – 26 October 2014
- Bonferroni and Hochberg corrections when making multiple statistical comparisons – 24 October 2014
- Risk of cataract with quetiapine and risperidone – 23 October 2014
- Ketamine treatment for depression: a meta-analysis – 18 October 2014
- Idalopirdine as an augmentation agent in Alzheimer – 15 October 2014
- Antidepressant initiation and suicidal ideation – 23 September 2014
- Treatment of trichotillomania: a meta-analysis – 14 September 2014
- Paroxetine in GAD and depression: a meta-analysis – 10 September 2014
- Vitamin D and the risk of dementia – 08 September 2014

View these paper reviews online at www.bap.org.uk/paperreviews.
You must have an up-to-date subscription to read these reviews.

Online CPD Resource

Latest updates to the resource include:

Substance Misuse:
Pharmacological management of comorbidity (psychosis, bipolar disorder, depression, anxiety), updated 21/5/2015

New topic now available

Substance Misuse:
Epidemiological approaches to studying causality: Cannabis use and psychosis, added 18/5/2015

www.bap.org.uk/onlinecpd
Education Events

Certificate in Clinical Psychopharmacology

Overview
Psychopharmacology is the single most commonly used treatment modality in psychiatry. It is vital we use drugs to their optimal effect – matching our choices and regimes to the needs and symptoms of patients whilst minimising side effects and avoiding adverse interactions with other drugs. New drugs and new ways of using old ones regularly appear. With ever increasing demands on our professional time it is difficult to keep up to date. This programme for CPD in state-of-the-art psychopharmacology is tailored to emphasise practical everyday problems encountered by all prescribing psychiatrists.

Content includes:
- lectures
- workshops
- discussion sessions

Forthcoming Modules

| Drug Treatments in Affective Disorders | 17th September 2015 – 18th September 2015 | Newcastle |
| Drug Treatments in Old Age Psychiatry | 22nd October 2015 – 23rd October 2015 | Newcastle |
| Anxiety Disorders | 21st January 2016 – 22nd January 2016 | Bristol |
| Child & Adolescent Psychopharmacology | 10th March 2016 – 11th March 2015 | Nottingham |
| Schizophrenia | May 2016 | Manchester |
| Substance Misuse | June 2016 | Manchester |

Registration fees
£350 per 1.5 day module
To book a place go to www.bap.org.uk/certificate

Masterclasses in Clinical Psychopharmacology

Overview
The Masterclasses are held over three consecutive days, twice a year. You can register for one, two or all three days, depending on your needs and interests. The full three day package is intended to provide a state-of-the-art update in psychopharmacology for clinicians.

Content includes:
- a review of the basic pharmacology of the relevant drugs
- the clinical use of those drugs
- discussions around relevant BAP and NICE guidelines
- questions and discussion with the speakers

Forthcoming Modules

| Day A | Schizophrenia Substance Misuse | 25th Nov 2015 | Hallam Conference Centre 44 Hallam Street London W1W 6JJ |
| Day B | Bipolar Perinatal ADHD | 26th Nov 2015 |
| Day C | Depression Anxiety Sleep | 27th Nov 2015 |

Registration fees
£310 per day
£840 for all three days
To book a place go to www.bap.org.uk/masterclasses
ONLINE CPD RESOURCE

A high quality, up-to-date resource taught by top experts in their field

- Schizophrenia
- Substance Misuse Including Comorbidity
- Bipolar Disorder
- Perinatal Disorders
- ADHD Focussing On Adult
- Depression
- Anxiety Disorders
- Sleep
- Old Age
- Child and Adolescent *
- General Psychopharmacology

Reviews of recent psychopharmacology papers, regularly updated

PLUS

Multiple Choice Questions, printable certificate on completion and reading lists

For more information and to subscribe go to www.bap.org.uk/onlinecpd

£120 per year
non-members

£60 per year
members and those who have registered or attended recent BAP meetings/courses

£45 per year
multiple users (10+)

* MCQs not currently available for this module
Exploiting the new pharmacology and application to drug discovery

BPS supported focused meeting in association with NC-IUPHAR

The focus will be on new concepts and developments in pharmacology and how they can be exploited in drug discovery including: new strategies for targeting calcium channels, tyrosine kinases, microRNAs, epigenetics, new developments in monoclonal antibodies, allosteric modulators, biased signalling, receptor structure. The meeting will include invited expert speakers, contributed free communications and poster presentations, with prizes for young investigators.

Bursaries
Available to BPS members who are presenting a poster or an oral at the meeting.

Keynote speakers:
Sir Colin Dollery, GlaxoSmithKline, UK - Anthony Harman Memorial Lecture
Bill Catterall, University of Washington, USA

Speakers:
Andrew Baker, University of Glasgow, UK
Anthony Davenport, University of Cambridge, UK
Chris Langmead, Monash University, Australia
Francesca Levi-Schaffer, Hebrew University of Jerusalem, Israel
Fiona Marshall, Heptares Therapeutics, UK
Alex Phipps, Roche Pharmaceuticals, UK
Rab Prinjha, GlaxoSmithKline, UK
Helgi Schiöth, Uppsala University, Sweden
Mary Vore, University of Kentucky, USA

For more information or to register your interest please contact:
t: +44 (0)207 239 0176
e: meetings@bps.ac.uk
w: www.bps.ac.uk

Supported by:
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences:

MONASH University
Institute of Pharmaceutical Sciences